Deacetylation of the NLRP3 Inflammasome as a Way to Control Chronic Inflammation

Chronic inflammation is an important component of degenerative aging. Excessive inflammatory signaling and activation of the immune system arises due to a combination of many factors, of which some are more important than others, such as the presence of lingering senescent cells. Most of the research focused on controlling inflammation is more interested in sabotaging the mechanisms of control than in removing root causes, however. The work here is an example of the type, in which scientists identify an important feature of the regulatory system controlling inflammation. Forcing a sizable reduction of inflammation via this regulatory system is a fairly blunt tool, as some degree of transient inflammation is vital to health, such as in the response to infection or injury. Nonetheless, the benefits may be large enough to outweigh the side-effects, as is the case for a number of past approaches to limiting inflammation in, for example, the treatment of autoimmune conditions. Chronic inflammation, which results when old age, stress, or environmental toxins keep the body's immune system in overdrive, can contribute to a variety of devastating diseases, from Alzheimer's and Parkinson's to diabetes and cancer. Researchers now show that a bulky collection of immune proteins called the NLRP3 inflammasome - responsible for sensing potential threats to the body and launching an inflammation response - can be essentially switched off by removing a small bit of molecular matter i...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs

Related Links:

PURPOSE: Results examining associations between metabolic syndrome (MetS) and depression, as well as on quality of life (QoL), are inconsistent. We aimed to determine whether individuals with MetS had decreased mental health-related QoL (MH-QoL) and higher...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
There is an urgent need to share expertise and offer emergency guidance for breast radiation therapy (RT) during the COVID-19 (Coronavirus) pandemic. As per the World Health Organisation (WHO) statement, our aim and obligation should be “to stop, contain, control, delay and reduce the impact of this virus at every opportunity”. In our roles as healthcare professionals and/or breast cancer experts this translates to minimising exposure of our patients to COVID-19 without compromising oncological outcome.
Source: Clinical Oncology - Category: Radiology Authors: Tags: Editorial Source Type: research
Purpose: The availability of novel imaging modalities (NIM) in prostate cancer (PCa) has overtaken the evidence informing their use. The recent EORTC consensus statement on modern imaging recognises the need for large-scale clinical trials of novel imaging [1]. The UK environment is well placed to conduct such trials; the NCRI prostate cancer CSG wished to benchmark current UK imaging availability and practice to inform future national trials.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: The role of pelvic nodal irradiation in prostate cancer remains controversial. Nevertheless, many high-risk patients are treated with prostate and pelvis radiotherapy in addition to androgen deprivation therapy (ADT) [1]. A recent retrospective study [2] and data from the UK Stampede control arm [3] suggest that radiotherapy may be of benefit to node positive patients. The aim of our study was to document outcomes in patients with node positive prostate cancer treated with pelvic nodal radiotherapy in a UK cancer centre.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: Relapsed or progressive prostate cancer frequently manifests as consecutive PSA rises long before disease is clinically detectable. Imaging with novel radiotracers targeting prostate-specific membrane antigen (PSMA) has been shown to be more sensitive in identifying the site of disease at lower PSA levels compared with conventional imaging, which may provide increased opportunity for salvage therapy, more aggressive local management of oligometastatic disease or increased confidence in proceeding with systemic therapy [1].
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: To assess the benefits and risks of co-administering maintenance prednisolone with docetaxel and androgen-deprivation therapy (ADT) in hormone sensitive metastatic prostate cancer (HSMPC).
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: As doctors we are required to take consent for radiotherapy; we typically take written consent [1]. We must tell a patient if a treatment might result in a serious adverse outcome, even if the likelihood is very small [2]. As many cancer centres move towards tumour site-specific consent forms for prostate radiotherapy we wanted to ascertain if there was consensus.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
In this study, we describe our experience with both drugs at the Diana Princess of Wales Hospital (DPoW), Grimsby.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: Synchronous chemotherapy with mitomycin C and 5-FU with radiotherapy may have an additional benefit over radiotherapy alone [1]. We looked into the rate of recurrence and median overall survival between these two groups of patients.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: The use of FDG PET has become more readily available over the past 15 years. It can be used to aid initial staging of testicular tumours and also assess the response to treatment in the metastatic setting, especially as residual masses are frequently seen after chemotherapy. There have been some recent concerns that FDG PET used to assess for residual disease may have a low positive predictive value [1]. A retrospective audit was carried out to look at the performance of FDG PET in seminoma patients treated at the Edinburgh Cancer Centre.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
More News: Alzheimer's | Autoimmune Disease | Cancer | Cancer & Oncology | Dementia | Diabetes | Diabetes Type 2 | Endocrinology | Environmental Health | Genetics | Insulin | Metabolic Syndrome | Multiple Sclerosis | Parkinson's Disease | Research | Stem Cell Therapy | Stem Cells